US2023399285A1PendingUtilityA1

Illudin analogs, uses thereof, and methods for synthesizing the same

70
Assignee: LANTERN PHARMA INCPriority: Sep 4, 2018Filed: Aug 27, 2023Published: Dec 14, 2023
Est. expirySep 4, 2038(~12.1 yrs left)· nominal 20-yr term from priority
C07C 49/573C07C 275/64C07C 2603/94C07B 2200/07C07C 29/76C07C 239/18C07C 45/29C07C 49/513A61P 35/00C07C 231/10C07C 231/24A61K 31/17C07C 2603/12
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A process for synthesizing compounds having the formula (III): 
       
         
           
           
               
               
           
         
       
       wherein Ri, R 2  and R 3  are independently (C1-C4) alkyl, methyl, or hydroxyl, comprising the steps of
 selecting a cyclopentenone having an alcohol group; 
 protecting the alcohol group; 
 reacting the protected cyclopentenone with a diazoketone to form a cycloadduct; and reducing the cycloadduct. 
 
     
     
         2 . The method according to  claim 1 , wherein the cyclopentenone of step a is selected from the group consisting of substituted cyclopentenones. 
     
     
         3 . The method according to  claim 1 , wherein the cleaving of the oxy group is achieved through the use of a suitable acid or base. 
     
     
         4 . The process according to  claim 1 , wherein the diazoketone is derived from a diazo compound and a ketone. 
     
     
         5 . The process of  claim 1 , wherein R1, R2, and R3 are each independently selected from (C1-C4) alkyl groups. 
     
     
         6 . The process of  claim 1 , further comprising oxidizing the cleaved cycloadduct to obtain hydroxyureamethylacylfulvene (+). 
     
     
         7 . The method according to  claim 6 , further comprising isolating hydroxyureamethylacylfulvene (+) after step g) using standard purification techniques. 
     
     
         8 . A method for synthesizing enantiopure acylfulvene, hydroxymethyl acylfulvene (HMAF), and hydroxyureamethylacylfulvene (UMAF) utilizing an enzymatic resolution of Compound 9 (Scheme 5). 
       
         
           
           
               
               
           
         
       
     
     
         9 . A method of synthesizing hydroxyureamethylacylfulvene (+) comprising the steps of:
 a) selecting a cyclopentenone having an alcohol group;   b) protecting the alcohol group of the selected cyclopentenone;   c) reacting the protected cyclopentenone with a diazoketone to form a cycloadduct;   d) Reducing the cycloadduct obtained in step c;   e) Alkylating a ketone group of the reduced cycloadduct;   f) Cleaving an oxy group of the alkylated cycloadduct; and   g) Oxidizing the cleaved cycloadduct to obtain hydroxyureamethylacylfulvene (+).   
     
     
         10 . The method according to  claim 9 , wherein the cyclopentenone of step a is selected from the group consisting of substituted and unsubstituted cyclopentenones. 
     
     
         11 . The method according to  claim 9 , wherein the protecting group used in step b is selected from the group consisting of acetyl, benzyl, tert-butyldimethylsilyl (TBDMS), and tert-butoxy carbonyl groups. 
     
     
         12 . The method according to  claim 9 , wherein the cleaving of the oxy group in step f is achieved through the use of a suitable reagent, such as an acid or base. 
     
     
         13 . The method according to  claim 9 , wherein the alkylating agent used in step 5 is selected from the group consisting of alkyl halides, alkyl sulfonates, and alkyl tosylates. 
     
     
         14 . The method according to  claim 9 , wherein the alkylating agent of step e) is an alkyl halide. 
     
     
         15 . The method according to  claim 9 , further comprising isolating hydroxyureamethylacylfulvene (+) after step g by standard purification techniques.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.